Quarterly report [Sections 13 or 15(d)]

Subsequent Events

v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events

Note 16—Subsequent Events

 

The Company has evaluated subsequent events through November 16, 2026, the date these condensed consolidated financial statements were available to be issued, and identified the following items:

 

Nasdaq Minimum Bid Price Deficiency Notice

 

On November 6, 2026, the Company received a written notice from Nasdaq stating that the Company no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company has until May 5, 2027 to regain compliance.

 

Consent and Warrant Exchange Agreement

 

On November 15, 2026, the Company entered into a Consent and Warrant Exchange Agreement with PharmaCyte Biotech, Inc., a related party (see Note 11). Under the agreement, PharmaCyte agreed to exchange 851,304 Series G Long-Term Warrants for an aggregate of 4,982,272 shares of Common Stock, determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Company’s Common Stock on the last trading day prior to execution of the agreement, and PharmaCyte consented to a six-month extension of the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027. The exchange is expected to close on or about November 16, 2026. As a result of the issuance of the exchange shares, and pursuant to the anti-dilution provisions of the applicable certificates of designations and warrants, the conversion price of the Series G Preferred Stock and Series H Preferred Stock and the exercise price of certain series of the Company’s outstanding warrants were adjusted to $0.3101 per share. The Company is evaluating the accounting for these transactions, which will be recorded in the fourth quarter of 2026. See Part II, Item 5 of this Quarterly Report.